Trial Information
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies
Sponsor: Inspirna, Inc
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
